"Bezafibrate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
| Descriptor ID |
D001629
|
| MeSH Number(s) |
D02.065.277.067 D02.241.081.114.968.500.249 D02.241.223.100.100.120 D02.241.223.100.200.249 D02.355.726.305.249 D02.455.426.559.389.127.085.101 D02.455.426.559.389.127.250.249 D02.455.426.559.389.657.654.305.249
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Bezafibrate".
Below are MeSH descriptors whose meaning is more specific than "Bezafibrate".
This graph shows the total number of publications written about "Bezafibrate" by people in this website by year, and whether "Bezafibrate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bezafibrate" by people in Profiles.
-
Khuchua Z, Glukhov AI, Strauss AW, Javadov S. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases. Int J Mol Sci. 2018 Nov 04; 19(11).
-
Huang Y, Powers C, Moore V, Schafer C, Ren M, Phoon CK, James JF, Glukhov AV, Javadov S, Vaz FM, Jefferies JL, Strauss AW, Khuchua Z. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome. Orphanet J Rare Dis. 2017 03 09; 12(1):49.
-
Foster JE, Gott K, Schuyler MR, Kozak W, Tesfaigzi Y. LPS-induced neutrophilic inflammation and Bcl-2 expression in metaplastic mucous cells. Am J Physiol Lung Cell Mol Physiol. 2003 Aug; 285(2):L405-14.
-
Tesfaigzi Y. The role of apoptotic regulators in metaplastic mucous cells. Novartis Found Symp. 2002; 248:221-30; discussion 230-6, 277-82.